Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435214 · ClinicalTrials.gov registry record
Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 131,110
- Enrollment target
NCT00435214: Completed study, sponsored by National Cancer Institute (NCI).
NCT00435214 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 131,110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00435214 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 131,110 participants
- Enrollment target
Study Summary
Background: * In most women, HPV infection does not cause symptoms and the infection goes away on its own. In a small percentage of women, the HPV infection does not go away and sometimes can result in cervical precancer or cancer. * There are several different types of HPV. A better understanding of which types are related to cervical precancer and cancer may help guide doctors in clinical management of women who test positive for HPV and better understand why some women develop disease while others do not. Objectives: * To determine whether certain types of HPV are more risky than others and if so, whether they warrant separate detection in screening for cervical precancer and cancer. * To determine if lasting infection by different HPV types carry different risk of cervical precancer and cancer. * To determine what viral and genetic factors influence the development of cervical precancer and cancer. * To evaluate new HPV tests and new biomarkers of cervical cancer risk. Eligibility: -Women 30 years of age and older who are in the cervical cancer screening program at the Kaiser Permanente health plan in Northern California. Women who tested positive for HPV and a random sample of women who tested negative for the virus are included. Design: -Data about participants genetic background and the type of carcinogenic HPV with which they are infected are analyzed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131,110 participants |
| Start Date | 2007-01-29 |
| Est. Completion | 2020-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435214
The ClinicalTrials.gov registry entry for NCT00435214 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 131,110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00435214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435214 about?
NCT00435214 is a clinical study titled "Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer". Background: * In most women, HPV infection does not cause symptoms and the infection goes away on its own. In a small percentage of women, the HPV infection does not go away and sometimes can result in cervical precancer or cancer. * There are several different types of HPV. A better understanding ...
What is the current status of trial NCT00435214?
This trial is currently completed. The enrollment target is 131,110 participants. The study started on 2007-01-29. Estimated completion is 2020-04-30.
Who is sponsoring clinical trial NCT00435214?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.